Walk through any hospital pharmacy and you will find the same story playing out in slow motion: shelves stocked with medications approaching expiration, partial vials that never get reconciled, and returned drugs sitting in a bin waiting for someone to figure out what to do with them.

None of that is waste by accident. It is waste by default — the result of systems that were never designed to recover value. The good news is that the same medications creating that drag on your budget can, with the right processes, become a meaningful source of recovered revenue.

Here is how high-performing hospital pharmacies are making that shift.

Most pharmacy directors know their drug spend down to the dollar. Far fewer know how much of that spend is sitting on shelves past its useful life, miscounted in the system, or quietly expiring before anyone flags it.

The average hospital pharmacy carries between 3% and 8% variance between its physical inventory and its system records. On a $2 million annual drug budget, that is anywhere from $60,000 to $160,000 in unaccounted medication — some of it recoverable, some of it already lost.

That variance compounds in two directions. Overstock means you are tying up capital in drugs you do not need. Understock means emergency purchases at premium pricing. Both erode margin.

The fix is not more staff. It is a more rigorous count methodology — one that catches discrepancies before they become write-offs.

When a trained pharmacy inventory team comes in with barcode scanners and a structured methodology, the results tend to surprise even experienced pharmacy directors.

A typical count surfaces:

• Near-expiry stock that can still be returned to the manufacturer or wholesaler for credit before the window closes
• Overstocked items that can be redistributed across a health system rather than purchased again at another facility
• Discrepancies between physical counts and system records that, once corrected, improve purchasing decisions for the next 12 months
• Controlled substance reconciliation gaps that create compliance exposure if left unaddressed

The count itself is not the value. The actionable data it produces is. A 99% accurate count gives your pharmacy team a clean baseline to work from — and a clear picture of exactly where the recovery opportunity sits.

If inventory counting is about knowing what you have, reverse distribution is about recovering value from what you cannot use.

Every year, hospital pharmacies discard medications that could have generated manufacturer credits. The reasons vary — expired product, discontinued NDCs, recalled lots, overpurchased stock — but the outcome is the same: money that could have come back to the pharmacy ends up in a waste bin instead.

A properly run reverse distribution program captures that value. Here is how it works in practice:

Step 1: Segregation and identification. Expired, recalled, and discontinued medications are pulled from active inventory and sorted by return eligibility. Not everything qualifies — DEA Schedule II–V controlled substances have specific handling requirements, and some manufacturers have narrow return windows — so accurate identification at this stage is critical.

Step 2: Credit calculation. Eligible medications are valued against current manufacturer return policies. This is where experience matters. A team that processes returns for hundreds of facilities knows which manufacturers offer full credit, which offer partial, and which have recently changed their policies.

Step 3: DEA-compliant destruction for non-returnables. Medications that cannot be returned must be destroyed in compliance with DEA and EPA regulations. Improper disposal is not just an environmental issue — it is a liability that can result in significant fines.

Step 4: Documentation and reporting. Every item processed generates a paper trail. For facilities subject to 340B audits or DEA inspections, that documentation is not optional.

When this process is run well, most hospital pharmacies recover between 20% and 30% of what they would otherwise write off entirely.

For hospitals operating under the 340B Drug Pricing Program, the stakes around medication management are even higher.

340B allows covered entities to purchase outpatient drugs at significantly reduced prices — but the compliance requirements are strict. Duplicate discounts, diversion, and inadequate record-keeping can trigger audits that result in repayment obligations and program termination.

Accurate inventory is not just a financial best practice for 340B facilities. It is a compliance requirement. Every unit of medication needs to be traceable from purchase to patient or return. A clean, documented inventory count is the foundation that makes that traceability possible.

Reverse distribution adds another layer of complexity for 340B entities, because the credit value of a returned drug depends on whether it was purchased at 340B pricing or WAC. Getting that wrong — in either direction — creates audit exposure.

The shift from pharmacy-as-cost-center to pharmacy-as-profit-contributor does not happen through a single initiative. It happens through a set of disciplines that compound over time:

Annual or semi-annual physical counts that give you a clean, accurate baseline and surface recovery opportunities before they expire.

A standing reverse distribution process rather than a reactive one. Waiting until you have a backlog of expired product means missing return windows and processing a larger, more complex job under time pressure.

Controlled substance reconciliation that keeps your DEA records clean and your team protected from compliance exposure.

Data-driven purchasing informed by accurate on-hand counts rather than gut feel or habit. The single biggest driver of overstock in hospital pharmacies is purchasing decisions made against inaccurate system data.

Vendor partnerships that understand healthcare compliance. Reverse distribution is not a logistics problem. It is a regulatory one. Your vendor needs DEA licensure for Schedule II–V handling, EPA compliance for hazardous waste, and state licensure in every state where they operate.

A regional health system with four hospital campuses and a combined annual drug spend of $8 million brought in a professional inventory team for the first time in three years. The count revealed $340,000 in near-expiry stock that was still within the manufacturer return window. A reverse distribution run processed $180,000 in credits — money that went directly back into the pharmacy budget.

The following year, with a clean baseline and a standing reverse distribution schedule, the same system reduced its drug spend variance from 6.2% to 0.9% and recovered an additional $210,000 in credits.

That is not an outlier. It is what happens when pharmacy operations are treated with the same financial discipline as any other department in the hospital.

Hospital pharmacies are not inherently cost centers. They are cost centers by default — because the processes that would recover value are either absent, inconsistent, or handled by teams without the specialized expertise to do them well.

The medications on your shelves represent real money. Some of it is still recoverable. The question is whether you have a process in place to capture it before the window closes.

If you are not sure where your pharmacy stands, a professional inventory count is the fastest way to find out. The data it produces will tell you exactly where the opportunity is — and what it is worth.